Literature DB >> 15367702

In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.

Salvatore DeBonis1, Dimitrios A Skoufias, Luc Lebeau, Roman Lopez, Gautier Robin, Robert L Margolis, Richard H Wade, Frank Kozielski.   

Abstract

Human Eg5, a member of the kinesin superfamily, plays a key role in mitosis, as it is required for the formation of a bipolar spindle. We describe here the first in vitro microtubule-activated ATPase-based assay for the identification of small-molecule inhibitors of Eg5. We screened preselected libraries obtained from the National Cancer Institute and identified S-trityl-L-cysteine as the most effective Eg5 inhibitor with an IC50 of 1.0 micromol/L for the inhibition of basal ATPase activity and 140 nmol/L for the microtubule-activated ATPase activity. Subsequent cell-based assays revealed that S-trityl-L-cysteine induced mitotic arrest in HeLa cells (IC50, 700 nmol/L) with characteristic monoastral spindles. S-trityl-L-cysteine is 36 times more potent for inducing mitotic arrest than the well-studied inhibitor, monastrol. Gossypol, flexeril, and two phenothiazine analogues were also identified as Eg5 inhibitors, and we found that they all result in monoastral spindles in HeLa cells. It is notable that all the Eg5 inhibitors identified here have been shown previously to inhibit tumor cell line growth in the NCI 60 tumor cell line screen, and we conclude that their antitumor activity may at least in part be explained by their ability to inhibit Eg5 activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367702

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  83 in total

1.  Allosteric drug discrimination is coupled to mechanochemical changes in the kinesin-5 motor core.

Authors:  Elizabeth D Kim; Rebecca Buckley; Sarah Learman; Jessica Richard; Courtney Parke; David K Worthylake; Edward J Wojcik; Richard A Walker; Sunyoung Kim
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

2.  Structure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors.

Authors:  Naohisa Ogo; Yoshinobu Ishikawa; Jun-Ichi Sawada; Kenji Matsuno; Akihiro Hashimoto; Akira Asai
Journal:  ACS Med Chem Lett       Date:  2015-07-22       Impact factor: 4.345

3.  Getting in sync with dimeric Eg5. Initiation and regulation of the processive run.

Authors:  Troy C Krzysiak; Michael Grabe; Susan P Gilbert
Journal:  J Biol Chem       Date:  2007-11-25       Impact factor: 5.157

4.  Dynein, Lis1 and CLIP-170 counteract Eg5-dependent centrosome separation during bipolar spindle assembly.

Authors:  Marvin E Tanenbaum; Libor Macůrek; Niels Galjart; René H Medema
Journal:  EMBO J       Date:  2008-11-20       Impact factor: 11.598

Review 5.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

6.  NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site.

Authors:  Sarah S Learman; Catherine D Kim; Nathaniel S Stevens; Sunyoung Kim; Edward J Wojcik; Richard A Walker
Journal:  Biochemistry       Date:  2009-03-03       Impact factor: 3.162

7.  TD-60 is required for interphase cell cycle progression.

Authors:  Mythili Yenjerla; Andreas Panopoulos; Caroline Reynaud; Rati Fotedar; Robert L Margolis
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

8.  Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

Authors:  Robert Jones; Jacqueline Vuky; Tony Elliott; Graham Mead; José Angel Arranz; John Chester; Simon Chowdhury; Arkadiusz Z Dudek; Volker Müller-Mattheis; Marc-Oliver Grimm; Jürgen E Gschwend; Christian Wülfing; Peter Albers; Jianguo Li; Anna Osmukhina; Jeffrey Skolnik; Gary Hudes
Journal:  Invest New Drugs       Date:  2013-01-18       Impact factor: 3.850

9.  Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.

Authors:  Sentai Ding; Zuohui Zhao; Dingqi Sun; Fei Wu; Dongbin Bi; Jiaju Lu; Naidong Xing; Liang Sun; Haihu Wu; Kejia Ding
Journal:  Tumour Biol       Date:  2014-05-07

10.  Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries.

Authors:  Joshua D Deschamps; Jeffrey T Gautschi; Stephanie Whitman; Tyler A Johnson; Nadine C Gassner; Phillip Crews; Theodore R Holman
Journal:  Bioorg Med Chem       Date:  2007-08-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.